JP7768770B2 - Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤 - Google Patents

Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤

Info

Publication number
JP7768770B2
JP7768770B2 JP2021572339A JP2021572339A JP7768770B2 JP 7768770 B2 JP7768770 B2 JP 7768770B2 JP 2021572339 A JP2021572339 A JP 2021572339A JP 2021572339 A JP2021572339 A JP 2021572339A JP 7768770 B2 JP7768770 B2 JP 7768770B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
inhibitor
hbv
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021572339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535879A (ja
Inventor
ゴワン，デイビッド，クレグ エムシー
ジャコビー，エドガー
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2022535879A publication Critical patent/JP2022535879A/ja
Application granted granted Critical
Publication of JP7768770B2 publication Critical patent/JP7768770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021572339A 2019-06-07 2020-06-05 Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤 Active JP7768770B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19179072.4 2019-06-07
EP19179072 2019-06-07
PCT/EP2020/065646 WO2020245372A1 (fr) 2019-06-07 2020-06-05 Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1

Publications (2)

Publication Number Publication Date
JP2022535879A JP2022535879A (ja) 2022-08-10
JP7768770B2 true JP7768770B2 (ja) 2025-11-12

Family

ID=66793871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572339A Active JP7768770B2 (ja) 2019-06-07 2020-06-05 Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤

Country Status (18)

Country Link
US (1) US20220259186A1 (fr)
EP (1) EP3980413B1 (fr)
JP (1) JP7768770B2 (fr)
KR (1) KR102939670B1 (fr)
CN (1) CN113966329B (fr)
AU (1) AU2020286962B2 (fr)
BR (1) BR112021023780A2 (fr)
CA (1) CA3138494A1 (fr)
ES (1) ES2956866T3 (fr)
HR (1) HRP20230873T1 (fr)
HU (1) HUE063236T2 (fr)
MA (1) MA56098B1 (fr)
MD (1) MD3980413T2 (fr)
MX (1) MX2021015048A (fr)
PL (1) PL3980413T3 (fr)
RS (1) RS64681B1 (fr)
SM (1) SMT202300280T1 (fr)
WO (1) WO2020245372A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006104062A (ja) 2003-09-17 2006-04-20 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
WO2018005374A1 (fr) 2016-06-27 2018-01-04 Chemocentryx, Inc. Composés immunomodulateurs
WO2018009505A1 (fr) 2016-07-08 2018-01-11 Bristol-Myers Squibb Company Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs
WO2018183171A1 (fr) 2017-03-27 2018-10-04 Bristol-Myers Squibb Company Dérivés d'isoquinoléine substitués utilisés en tant qu'immunomutateurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705489B (zh) * 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006104062A (ja) 2003-09-17 2006-04-20 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
WO2018005374A1 (fr) 2016-06-27 2018-01-04 Chemocentryx, Inc. Composés immunomodulateurs
WO2018009505A1 (fr) 2016-07-08 2018-01-11 Bristol-Myers Squibb Company Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs
WO2018183171A1 (fr) 2017-03-27 2018-10-04 Bristol-Myers Squibb Company Dérivés d'isoquinoléine substitués utilisés en tant qu'immunomutateurs

Also Published As

Publication number Publication date
MX2021015048A (es) 2022-01-18
EP3980413B1 (fr) 2023-07-19
JP2022535879A (ja) 2022-08-10
WO2020245372A1 (fr) 2020-12-10
ES2956866T3 (es) 2023-12-29
MA56098A (fr) 2022-04-13
MA56098B1 (fr) 2023-10-31
KR20220017942A (ko) 2022-02-14
US20220259186A1 (en) 2022-08-18
CN113966329B (zh) 2024-08-13
HUE063236T2 (hu) 2024-01-28
AU2020286962A1 (en) 2022-02-03
KR102939670B1 (ko) 2026-03-13
EP3980413A1 (fr) 2022-04-13
HRP20230873T1 (hr) 2024-02-16
MD3980413T2 (ro) 2023-12-31
CN113966329A (zh) 2022-01-21
RS64681B1 (sr) 2023-11-30
BR112021023780A2 (pt) 2022-01-11
PL3980413T3 (pl) 2023-12-27
EP3980413C0 (fr) 2023-07-19
AU2020286962B2 (en) 2025-10-16
CA3138494A1 (fr) 2020-12-10
SMT202300280T1 (it) 2023-11-13

Similar Documents

Publication Publication Date Title
ES3029140T3 (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
CN107922431B (zh) Hpk1抑制剂及其使用方法
JP6952695B2 (ja) インフルエンザウイルス複製の阻害剤、その適用方法および使用
US8299106B2 (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
BR102018007822A2 (pt) composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP2019505541A (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
KR20170081204A (ko) 제약 화합물
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
US11267824B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
JP7768770B2 (ja) Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤
CA3157778A1 (fr) Composes d'isoindolonyle 2,2'-bipyrimidinyle substitues, analogues de ceux-ci, et procedes les utilisant
RU2824127C2 (ru) Гетероциклические иммуномодуляторы в качестве ингибитора контрольных точек иммунного ответа pdl1
HK40067662A (en) Heterocyclic immunomodulators as pdl1 checkpoint inhibitor
WO2018187509A1 (fr) Composés hétérocycliques utilisés en tant que modulateurs du récepteur de chimiokine
WO2025003402A1 (fr) Inhibiteurs hétéroaromatiques de dhodh
HK40057478A (en) Hpk1 inhibitors and methods of using same
EA043549B1 (ru) Стимуляторы sgc

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7768770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150